Year: 2025

New leveraged ETPs on Spotlight (SEK): Bull Bitcoin X2 Valour and Bull Ethereum X2 Valour deliver 2x daily exposure to BTC and ETH in a regulated, exchange-traded format (no wallets or margin; 1.9% management fee). Designed for familiar Nordic workflows: Built for investors who want amplified exposure without digital wallets or margin accounts, leveraging the region’s long standing familiarity with Bull and Bear style products. Expanding beyond spot products: Strengthens Valour’s product breadth with structured and enhanced exposure offerings that complement its diversified lineup across next generation crypto themes.TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — DeFi Technologies (the “Company” or “DeFi Technologies”) (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital...

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM), to improve exercise capacity and symptoms. Under the terms of its license and collaboration agreement with Cytokinetics, Sanofi has exclusive rights to develop and commercialize MYQORZO for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. The approval...

WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) announces that it presented new clinical and scientific data at the Innovations in Wound Healing (“IWH”) Annual Meeting, which took place in Key West, Florida December 11-14, 2025.  At this year’s conference, Kane Biotech shared case study data from across its wound care portfolio, underscoring the company’s commitment to addressing complex and high-burden health conditions. The link to the presentations can be found here and include:Clinical outcomes reported from case studies using Kane’s advanced wound gel platform, demonstrating improved healing trajectories in chronic wounds. Versatility over multiple sites and standards of care, featuring efficacy over different application frequencies, dressing and...

Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed LONDON and PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase 1a part of the study. Faridoxorubicin is the first peptide drug conjugate (PDC) in Avacta’s pipeline. It consists of...

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement with a new large global pharmaceutical customer. Under the terms of the agreement, Lifecore will conduct development services and tech transfer for an injectable pharmaceutical product with the intent to transfer commercial supply from facilities overseas to Lifecore’s facilities. Once commercial transfer activities are complete and all regulatory requirements...

Vancouver, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that is has staked an additional 90 claims, approximately 6 square kilometers or 1500 acres, with strong antimony-gold prospectivity at its Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada. The newly staked ground has the same geological signatures as other antimony-gold targets at the Project. Aerial Drone Footage of 2025 Drilling & High-Grade Antimony Bullet Zone Discovery (Click Here): Key HighlightsAdded an additional 90 claims, approximately 6 square kilometers or 1500 acres, with strong antimony-gold prospectivityThe new claims encompass remaining surface exposure of a dolomite-over-Pilot Shale thrust block, as well as exposed...

MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has issued a notice of partial redemption for US$500 million aggregate principal amount of its outstanding 6.000% Senior Notes due 2028 (the “2028 Notes”). As set forth in the notice of partial redemption issued today in respect of the 2028 Notes, the redemption date is February 15, 2026, and the redemption price for the 2028 Notes is 100% of the principal amount redeemed, plus accrued and unpaid interest. This debt redemption will be funded using cash from Bombardier’s balance sheet. On December 17, 2025, a copy of the notice of partial redemption with respect to the 2028 Notes was issued to the record holders thereof. Payment of the redemption price and surrender of the 2028 Notes for redemption will be made through the facilities...

Evolve commence trading on the CSE today, December 17, 2025 under the ticker symbol “EVR” Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Evolve Royalties Ltd. (CSE: EVR) (“Evolve” or the “Company”) is pleased to announce that its common shares have commenced trading on the Canadian Securities Exchange (the “CSE”) under the symbol “EVR.” “Today marks an important milestone for Evolve as we begin trading on the CSE,” said Joseph de la Plante, President & CEO of Evolve. “Over the past year, we have assembled a copper-focused royalty portfolio anchored by Highland Valley Copper and Copper Mountain—two of Canada’s largest copper operations—and most...

The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to treatment with osimertinib but subsequently acquired resistance to treatment Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib...

TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced it has exercised its right to call all 500,000 outstanding common share purchase warrants (the “Warrants”) issued in connection with its October 20, 2025 non-brokered private placement financing. The Warrants issued in connection with Abaxx’s October 2025 private placement contained a provision allowing Abaxx to exercise a redemption right to call the Warrants in the event the daily VWAP of Abaxx’s common shares traded on Cboe Canada...